Advertisement

SPERANZA project: HPV vaccination after treatment for CIN2+

Published:September 06, 2018DOI:https://doi.org/10.1016/j.ygyno.2018.08.033

      Highlights

      • After conization, HPV vaccine shows 80% clinical effectiveness in disease relapse prevention.
      • Clinical benefits of vaccination are demonstrated up to 4 years.
      • HPV vaccine has no therapeutic effect on prevalent HPV infection or disease.
      • HPV vaccination is beneficial as an adjuvant additional to surgical treatment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Human Papilloma Virus Vaccines: WHO Position Paper. Weekly Epidemiological Record, No. 15. 84. 2009: 117-132
        • Stanley M.A.
        Human papillomavirus vaccines.
        Rev. Med. Virol. 2006 May–Jun; 16: 139-149
        • Olsson S.E.
        • Kjaer S.K.
        • Sigurdsson K.
        • Iversen O.E.
        • Hernandez-Avila M.
        • Wheeler C.M.
        • Perez G.
        • Brown D.R.
        • Koutsky L.A.
        • Tay E.H.
        • García P.
        • Ault K.A.
        • Garland S.M.
        • Leodolter S.
        • Tang G.W.
        • Ferris D.G.
        • Paavonen J.
        • Lehtinen M.
        • Steben M.
        • Bosch F.X.
        • Dillner J.
        • Joura E.A.
        • Majewski S.
        • Muñoz N.
        • Myers E.R.
        • Villa L.L.
        • Taddeo F.J.
        • Roberts C.
        • Tadesse A.
        • Bryan J.
        • Maansson R.
        • Vuocolo S.
        • Hesley T.M.
        • Saah A.
        • Barr E.
        • Haupt R.M.
        Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.
        Hum. Vaccin. 2009 Oct; 5: 696-704
        • Luna J.
        • Plata M.
        • Gonzalez M.
        • et al.
        Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women.
        PLoS One. 2013; 8: e8343
        • Munoz N.
        • Manalastas Jr., R.
        • Pitisuttithum P.
        • et al.
        Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial.
        Lancet. 2009; 373: 1949-1957
        • Joura E.A.
        • Garland S.M.
        • Paavonen J.
        • Ferris D.G.
        • Perez G.
        • Ault K.A.
        • Huh W.K.
        • Sings H.L.
        • James M.K.
        • Haupt R.M.
        Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.; FUTURE I and II study group.
        BMJ. 2012 Mar 27; e1401: 344
        • Swedish K.A.
        • Factor S.H.
        • Goldstone S.E.
        Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study.
        Clin. Infect. Dis. 2012 Apr; 54: 891-898
        • Deshmukh A.
        • Cantor S.B.
        • Fenwick E.
        • Chiao E.Y.
        • Nyitray A.G.
        • Strier E.A.
        • Goldstone S.E.
        • Wilkin T.
        • Chhatwal J.
        Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: the time is now.
        Vaccine. 2017 Sep 12; 35: 5102-5109
        • Kin Cho Goon P.
        • Sholtz L.U.
        • Sudhoff H.
        Recurrent respiratory papillomatosis (RRP)-time for a reckoning?.
        Laryngoscope Investig. Otolaryngol. 2017 May 28; 2: 184-186
        • Swedish K.A.
        • Goldstone S.E.
        Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men.
        PLoSOne. 2014 Apr 8; 9e93393
        • Prendiville W.
        Appropriate use of leep interventions.
        J. Low Genit. Tract. Dis. 1998 Oct; 2: 254
        • Kang W.D.
        • Choi H.S.
        • Kim S.M.
        Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?.
        Gynecol. Oncol. 2013 Aug; 130: 264-268
        • Garland S.M.
        • Paavonen J.
        • Jaisamrarn U.
        • HPV PATRICIA Study Group
        • et al.
        Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high-grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial.
        Int. J. Cancer. 2016; 139: 2812-2826
        • Hildesheim A.
        • Gonzalez P.
        • Kreimer A.R.
        • Wacholder S.
        • Schussler J.
        • Rodriguez A.C.
        • Porras C.
        • Schiffmann M.
        • Sidawy M.
        • Schiller J.T.
        • Lowy D.R.
        • Herrero R.
        • Costa Rica HPV Vaccine Trial (CVT) Group
        Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
        J. Obstet. Gynecol. 2016 Aug; 215: 212-215
        • Song S.H.
        • Lee J.K.
        • Lee N.W.
        • Saw H.S.
        • Kang J.S.
        • Lee K.W.
        Interferon-gamma (IFN-gamma): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV).
        Gynecol. Oncol. 2008 Mar; 108: 543-548
        • Rosa M.I.
        • Moraes M.V.
        • Vuolo F.
        • Petronilho F.
        • Bozzetti M.C.
        • Medeiros L.R.
        • et al.
        Association of interleukin-6 in women with persistence of DNA-HPV: a nested case-control study.
        Arch. Gynecol. Obstet. 2012 Jan; 285: 143-148
        • Paradkar P.H.
        • Joshi J.V.
        • Mertia P.N.
        • Agashe S.V.
        • Vaidya R.A.
        Role of cytokines in genesis, progression and prognosis of cervical cancer.
        Asian Pac. J. Cancer Prev. 2014; 15: 3851-3864
        • Scott M.E.
        • Shvetsov Y.B.
        • Thompson P.J.
        • Hernandez B.Y.
        • Zhu X.
        • Wilkens L.R.
        • et al.
        Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study.
        Int. J. Cancer. 2013 Sep 1; 133: 1187-1196
        • Saftlas A.F.
        • Spracklen C.N.
        • Ryckman K.K.
        • Stockdale C.K.
        • Penrose K.
        • Ault K.
        • Rubenstein L.M.
        • Pinto L.A.
        Influence of a loop electrosurgical excision procedure (LEEP) on levels of cytokines in cervical secretions.
        J. Reprod. Immunol. 2015 Jun; 109: 74-83